From Bench to Bedside Faster, Safer, and with Fewer Surprises.
Nucelion is a next-generation Cell & Gene Therapy CDMO helping innovators accelerate their journey from discovery to clinical impact. With deep expertise in viral vectors (AAV, Lentivirus) and cell therapies (CAR-T, NK, iPSC-derived), we bring scientific precision and operational discipline under one roof.
Dr. Raghu Malapaka
CBO –Nucelion Therapeutics
Raghu Malapaka, Ph.D, CBO, Nucelion. Dr. Raghu Malapaka has an extensive commercial experience in the development and manufacturing of large molecules as well as advanced therapies. He served in leadership roles in global CDMOs including AGC Bio, Thermofisher and WuXi and played key role in bringing some of the earliest CGTs to the patients. He has a PhD in molecular biology and post-doctoral experience at Harvard Medical School.
What Makes Us Different
End-to-end mindset
Process + Analytics + Quality + Program Management in one loop, not siloed.
Right-sized capacity
~30,000 sft Dev Labs, GMP Suites, QC & Fill-Finish supporting AAV (2 campaigns/mo, 75–150 L), LVV (1–2/mo), CAR-T (10–20 lots/mo), and Plasmid (2–3 GMP lots/mo, 10–20 L & 75–150 L).
Regulatory pragmatism
CMC packages that actually pass muster—IND/IMPD-oriented documentation, ALCOA+ data integrity, and phase-appropriate validation.
Transparent Project Management
You’ll see Gantt updates, risk registers, and burn-rate vs. deliverables
Where We Operate
We’re headquartered in Genome Valley, Hyderabad, India, with GMP manufacturing, QC, and development labs under one roof.
Our location within India’s premier biotech hub provides access to world-class scientific talent, infrastructure, and collaboration opportunities that drive every program forward.
We partner with hospitals, biotech startups, and pharmaceutical companies that value responsiveness, precision, and accountability.
We do not oversell capacity — what we promise, we deliver.
